Best of ASCO - 2014 Annual Meeting



Esophageal or Gastric Cancer

Gastrointestinal (Noncolorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
KRAS amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA).

Joseph Chao


A digital pathology demonstration of an "immune hot" ICOS+/CD45RO+ immunephenotype and the impact on survival in patients with esophageal adenocarcinoma.

Matthew Philip Humphries


A landscape of circulating tumor DNA in esophageal adenocarcinoma and squamous cell carcinoma.

Kabir Mody


A multicenter, single-armed, prospective phase II study of apatinib combined with chemotherapy neoadjuvant for locally advanced gastric cancer.

JianXian Lin


A novel EUS-guided liquid fiducial marker for image-guided radiotherapy in esophageal cancer: The safety and efficacy in vitro and vivo evaluations.

Liangchao Sun


A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.

Yee Chao


A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.

Yi-Ping Hung


A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.

Tom van den Ende


A phase II study of S-1, oxaliplatin, and nab-paclitaxel, and itraconazole aimed at conversion surgery for advanced and recurrent gastric cancer.

Yoshihiko Nakamoto


A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Rutika Mehta


A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).

Min Hee Hong


A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results.

Jennifer Yon-Li Wo


A single-arm, open phase II clinical trial of anti-programmed death-1 antibody SHR-1210 combined with nimotuzumab as second-line treatment of advanced esophageal squamous cell carcinoma.

Feng Wang


Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).

Clarisse Eveno


Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).

Maria Alsina


Apatinib affects the proliferation, migration and apoptosis of esophageal cancer cells both in vitro and in xenografts by regulating Ras/Raf/MEK/ERK and JAK2/STAT3 signaling pathways.

Jingping Yu


Apatinib in the treatment of non-operable or advanced gastric cancer: Evidence of efficacy and safety in a real-world study.

Ligang Xing


Apatinib inhibits tumor progression and promotes antitumor efficacy of cytotoxic drugs in esophageal squamous cell carcinoma.

Yanyan Chi


ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).

Se Hoon Park


Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.

Federica Morano


Association between heart dosimetric parameters, cardiac events and overall survival for patients with stage III esophageal cancer treated with definitive radiotherapy.

Guoxin Cai


Association between molecular subtype of esophageal squamous cell carcinoma and survival of patients.

Denis S. Kutilin


Association of CDH1 mutation with prognosis in gastric adenocarcinoma.

Xiangyang Yu


Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade.

Feng Wang


Association of high copy number instability (CNI) score with prognosis in patients with gastric cancer after surgical resection.

Yanling Zhang


Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial.

Daniel Swinson


CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.

Kynan Feeney


Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.

Lin Shen


Can hormone receptors prevent metastatic spread of gastric cancer?

Irina V. Kaplieva


Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy.

Megan Greally


Clinical efficacy and safety in gastric cancer patients treated with apatinib: A retrospective real-world study.

Ning Li


Clinical implication of telomere length-related polymorphisms in gastric cardia adenocarcinoma.

Nasha Zhang


Clinical significance of peritoneal molecular markers in patients with locally advanced gastric cancer (LAGC) without macroscopic peritoneal implants treated with perioperative chemotherapy (ChT).

Luis Paul Del Carpio Huerta


Clinicopathological and prognostic significance of microsatellit instability (MSI) status and PDl-1 expression in Turkish patients with gastric cancer.

Ibrahim Yildiz


Clinicopathological features of Epstein–Barr virus associated gastric carcinoma with submucosal invasion.

Hiroki Osumi


Combining neoadjuvant chemoradiation with adjuvant chemotherapy in multimodality treatment for patients with potentially curable esophageal carcinoma.

Ruta Arays


Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: A randomized controlled study.

Pengfei Yu


Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.

Xiaoying Zhao


Comparison of tumor characteristics and survival between esophageal and other gastroenteropancreatic neuroendocrine neoplasms.

Mehran Taherian


Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling.

Seung Kim


Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.

Ken Masuda


Correlation of CHAF1A with adjuvant chemotherapy outcome and microsatellite instability in gastric cancer.

Deqiang Wang


Decreased risk of esophageal squamous cell carcinoma among metformin users in a population-based cohort study.

Qiao-Li Wang


Derived neutrophil-to-lymphocyte ratio and platelet to lymphocyte ratio as a prognostic marker for patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.

Guoxin Cai


Disassociation of ARID1A with genomic ancestry and prognostic impact in an admixed cohort of Brazilian patients with gastric cancer (GC).

Helano C. Freitas


Distribution of urokinase-type plasminogen activator and its receptor in malignant tissues of gastric adenocarcinoma.

Larisa S. Kozlova


Dosimetric and radiobiological comparison of external beam radiotherapy using simultaneous integrated boost technique for esophageal cancer in different location.

Lu Wang


Effect of p-PAQR3Thr32 on PD-L1 expression and immune evasion in gastric cancer.

Zhi-Qiang Ling


Efficacy and safety of conversion therapy using chemotherapy plus anti-angiogenic therapy in unresectable gastric cancer.

Lu chuan Chen


Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.

Zev A. Wainberg


Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).

Nong Xu


Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer.

Raghav Sundar


Esophageal cancer: Five years of experience in an oncological reference center.

José Carlos Cessa-Zanatta


Evaluation of prognostic factors after esophagectomy in which preoperative chemotherapy was successful.

Takashi Ogata


Expression of CD44 and CD133 in tumor сells of metastatic and non-metastatic gastric cancer.

Aleksandr B. Sagakyants


Factors predicting poor survival in early gastric cancer: A SEER analysis.

Yanal Mufeed Alnimer


Final results of early non-invasive gastric cancer detection study using the serum pepsinogen test method in Croatian patients.

Dragan Trivanovic


First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.

Yelena Yuriy Janjigian


FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO.

Sylvie Lorenzen


Genome-wide copy number alteration (CNA) of circulating cell-free DNA (cfDNA) as a prognostic biomarker in esophageal squamous cell carcinoma (ESCC).

Hyeon-Su Im


Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181).

Antoine Adenis


Homologous recombination deficiency as prognostic marker in metastatic gastric cancer.

Nuno Sousa


Identification of clinically actionable mutations and immunotherapy biomarkers in Chinese esophageal squamous cell carcinoma patients.

Minghui Wang


Immune biomarker expression in the tumor microenvironment in Chinese patients with esophageal squamous cell carcinoma was explored.

Pengfei Li


Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.

Lucy Xiaolu Ma


Impact of adjuvant treatment according to gastric cancer molecular subtypes.

Tiago Biachi De Castria


Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).

Avani Athauda


Impact of Clostridium difficile infection on gastrointestinal malignancies.

Stuthi Perimbeti


Integrating endogenous peptides analysis and protease mapping for identification of potential serum biomarkers in gastric adenocarcinoma.

Nora Manoukian Forones


Investigation of enhanced antitumor effects via co-inhibition of Wnt/β-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer.

Moon Young Choi


Investigation to metastasis of regional lymph node station and prediction to long-term survival following esophagectomy in thoracic esophageal cancer with stage T1 to T3.

Yin Li


Is it possible to effectively treat second-line gastric cancer, given the prognosis factors?

Georgy M. Manikhas


Is there a correlation between clinic-pathological features, MSI, PD-L1 and survival outcomes in resected gastric cancer? Looking for optimal biomarkers.

Margherita Ratti


KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.

Yelena Yuriy Janjigian


Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.

Xi Wang


Landscape of innate and adaptive immunity targets in oesophagogastric adenocarcinoma (OGA).

Elizabeth Catherine Smyth


Management of synchronous Krukenberg tumors from gastric cancer: A single-center experience.

Pengfei Yu


Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.

Salah-Eddin Al-Batran


Molecular comparison between peritoneal metastases (PM) and primary gastric (GC) and gastroesophageal junction (GEJ) cancer.

Matthew K Stein


Molecular mechanism of chemoresistance and restoration in human gastric cancer cells.

Hye Jung Chang


Neoadjuvant chemoradiotherapy combined with surgery in the treatment of potentially operable thoracic squamous cell carcinoma of the esophagus(ChiCTR-OIC-17011648): A phase II single center clinical study.

Fang Liu


Neoadjuvant epirubicyn, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study.

Antonino De Paoli


Neoadjuvant versus adjuvant chemoradiotherapy for stage II–III esophageal squamous cell carcinoma: A propensity score-matched analysis.

Jiahua Lv


Not all HLA loss facilitate immune escape.

Li Zhang


Novel genomic prognostic factors for nonsurgical esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy.

Honghai Dai


Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.

Peter S Hall


Paratracheal lymph node metastasis in operable localized esophageal and gastroesophageal junction adenocarcinoma.

Kazuto Harada


Patient-reported distress and symptoms predict post-esophagectomy outcomes.

Jonathan C. Salo


Patterns of local failure after definitive radiotherapy in patients with esophageal squamous cell carcinoma: Implications for the longitudinal clinical target volume design.

Bo Cheng


Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.

Ken Kato


Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Manish A. Shah


Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Josep Tabernero


Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA).

Daniel V.T. Catenacci


Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Salah-Eddin Al-Batran


Perioperative chemotherapy alone versus preoperative chemoradiotherapy for locally advanced distal esophageal and gastroesophageal junction cancer: A 10-year review of the British Columbia (BC) cancer registry.

Shiru Lucy Liu


PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.

Sylvie Lorenzen


Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases.

Sina Vatandoust


Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.

Bo Zhang


Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Jian-Ming Xu


Phase I study of irinotecan/5-fluorouracil/leucovorin (FOLFIRI) with sunitinib for advanced gastroesophageal cancers (EGC).

Sarbajit Mukherjee


Phase I trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.

Brian D. Badgwell


Phase II study of a telomerase-specific oncolytic adenovirus (OBP-301, Telomelysin) in combination with pembrolizumab in gastric and gastroesophageal junction adenocarcinoma.

Uqba Khan


POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.

Rongbo Lin


Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC).

Eric Van Cutsem


Postoperative adjuvant chemotherapy for thoracic pathological T3N0M0 esophageal cancer: A propensity score-matched analysis (APEC Study 1).

Qifeng Wang


Predictors of peritoneal metastasis in gastric cancer.

Irina V. Kaplieva


Preoperative CA 19-9 and CEA as predictors of operative outcomes in resectable gastric cancer (GC).

Alexandra Gangi


Prevalence of esophageal malignant and premalignant lesions in a Michigan cohort, 2013-2017.

Shilpa Tatineni


Prevalence of gastric cancer and premalignant changes in a Michigan cohort, 2013-2017.

Divyesh Reddy Nemakayala


Prognostic significance of sarcopenia in metastatic esophageal squamous cell carcinoma.

Kirsty Taylor


Prognostic stratification of locoregional esophageal cancer (EC) patients (pts) treated with definitive chemoradiotherapy (dCRT).

Hyehyun Jeong


Prognostic value and clinicopathological significance of programmed cell death ligand 1 (PD-L1) expression in resected gastric cancer: A meta-analysis.

Shuixiu Yu


Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.

Woochan Park


Prognostic value of systemic immune-inflammation index in elderly patients with esophageal squamous cell cancer.

Shengjun Ji


Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy.

Shin Hye Yoo


Prospective validation of a serum miRNA panel for early detection of gastric cancer.

Lihan Zhou


Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.

Haeseong Park


Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912).

Hitoshi Katai


RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).

Anica Högner


Recurrence risk evaluation in stage IB gastric cancer with TP53 codon 72 polymorphism.

Satoshi Nishizuka


Relationship between PET response and pathologic response in distal esophageal/gastroesophageal junction cancers: A provincial population-based analysis.

Irene S. Yu


Role of angiogenesis factors in formation of metastatic niches.

Elena M. Frantsiyants


S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.

Rui-hua Xu


Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consortium study.

Hirva Mamdani


Safety and efficacy of neoadjuvant chemotherapy with S-1 and oxaliplatin plus apatinib for locally advanced gastric cancer.

Ya'nan Zheng


Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.

Nataliya Volodymyrivna Uboha


Safety results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai 2).

Dashan Ai


Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.

Brianna Lauren


Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).

Di Maria Jiang


Survival analysis and clinical characteristics of forty-eight patients with alpha-fetoprotein-positive gastric cancer treated by integrated Chinese and western medicine.

Wenting He


Survival of gastric cancer (GC) patients is not determined by the predominant genomic ancestry (PGA): Results from an ethnically admixed Brazilian cohort of GC patients.

Helano C. Freitas


Targeting of survivin to overcome cisplatin resistance in esophageal adenocarcinoma.

Rosalie V. Douglas


TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.

Hideaki Bando


The ctDNA in peritoneal effusion of advanced gastric cancer for auxiliary diagnosis of peritoneal metastasis.

Changsong QI


The genetic profiles of esophageal squamous cell carcinoma (ESCC) in Hebei, a northern province of China.

Jing Zuo


The impact of method of recurrence detection on esophageal/gastroesophageal junction (EGJ) cancer outcomes.

Jubin Eghbali Matloubieh


The impact of postoperative complications on survival outcomes in patients with cT3/4a gastric cancer.

Masanori Tokunaga


The mutational profile analysis of different response to neoadjuvant chemoradiation therapy in local advanced esophageal squamous cell cancer patients.

Xiaofeng Wang


The prognostic factors associated with long-term survival in the patients with synchronous oligometastatic esophageal adenocarcinoma.

Masaaki Iwatsuki


The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT).

Richard Malthaner


The ratio of negative lymph node count inside the thoracic cavity to the positive lymph count is a prognostic factor in esophageal squamous cell carcinoma.

Jinling Zhang


The regulation effect of EGFR signaling pathway on PD-L1 expression on esophageal squamous cell carcinoma cell lines.

Ran Lin Wang


Tissue plasminogen activator in gastrointestinal adenocarcinoma: What is its role?

Andrey A. Maslov


Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience.

Megan Greally


tPA and PAI-1 in malignant tissues of gastric adenocarcinoma can be tumor-associated.

Nikolay S. Samoylenko


Treatment modalities and oncological outcomes in a cohort of patients with advanced gastric cancer in Mexico.

Ana Karen Valenzuela


Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE).

Shukui Qin


Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Kohei Shitara


Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS.

Wasat Mansoor


Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers.

Bo Han


Tumor mutation burden and immunogenicity in gastric cancer with HER2 alterations.

Bo Wei


Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody.

Rui-Hua Xu


Urokinase secretion by gastrointestinal adenocarcinoma.

Larisa S. Kozlova